^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Excerpt:
This acquired L1198F mutation conferred resistance to lorlatinib, but unexpectedly restored sensitivity to crizotinib, a less potent and less selective first-generation inhibitor.
DOI:
10.1056/NEJMoa1508887